Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

Core Insights - Tarsus Pharmaceuticals reported record quarterly net product sales of $102.7 million for Q2 2025, marking a 152% increase year over year, driven by the successful launch of XDEMVY [1][5] - The Direct-To-Consumer campaign has significantly increased patient engagement and prescriptions, with active consumer engagement on the XDEMVY website up nearly 400% since the start of 2025 [5] - The company is on track with its pipeline advancements and global expansion efforts, including plans for regulatory meetings in Japan and potential European approval for a preservative-free formulation of XDEMVY [5][10] Recent Business and Clinical Highlights - XDEMVY has established itself as the standard of care for Demodex blepharitis, with over 91,000 bottles distributed in Q2 2025 [2][5] - More than 20,000 Eye Care Professionals (ECPs) are now prescribing XDEMVY, a 30% increase since the beginning of 2025 [5] - The company plans to initiate a Phase 2 study of TP-04 for ocular rosacea in H2 2025 and a Phase 2 study of TP-05 for Lyme disease prevention in 2026 [5] Financial Results - For Q2 2025, product sales were $102.7 million compared to $40.8 million in Q2 2024, with a total of approximately 91,000 bottles delivered [5][10] - Cost of sales increased to $6.2 million from $3.0 million in the same period last year, primarily due to manufacturing costs related to XDEMVY [10] - Research and development expenses rose to $15.6 million from $12.3 million in Q2 2024, driven by increased program expenses and personnel-related costs [6][10] Year-to-Date Financial Performance - Year-to-date product sales reached $181.0 million, up from $65.5 million in the same period in 2024 [10] - Selling, general and administrative expenses increased to $188.0 million from $110.4 million, largely due to higher commercial and marketing costs associated with the XDEMVY launch [10] - The net loss for the year-to-date period was $45.5 million, an improvement from a net loss of $69.0 million in the same period in 2024 [10]